Insmed is rated a hold, reflecting a robust therapeutic pipeline but persistent unprofitability, and is priced at a high ...

And then finally, by amplifying our enterprise capabilities that we're doing things once across the organization, and we're really bringing the breadth and depth of S&P Global together and with all ...